Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors

In this article, we will discuss the top 5 stock picks of Samuel Isaly’s OrbiMed Advisors. If you want to read our detailed analysis of Isaly’s history, investment philosophy, and hedge fund performance, go directly to Top 10 Stock Picks of Samuel Isaly’s OrbiMed Advisors.

5. Bristol-Myers Squibb Company (NYSE:BMY)

OrbiMed Advisors Stake Value: $267,176,000
Percentage of OrbiMed Advisors’ 13F Portfolio: 2.93%
Number of Hedge Fund Holders: 74

Bristol-Myers Squibb Company (NYSE:BMY) is a pharmaceutical company that specializes in chemically manufactured drugs and biologics. Bristol-Myers Squibb Company (NYSE:BMY) issued a quarterly dividend of $0.54 per share in December, up 10.2% from the previous payout of $0.49.

As of the end of the third quarter, legendary investor and billionaire Warren Buffett’s Berkshire Hathaway is the largest shareholder in Bristol-Myers Squibb Company (NYSE:BMY) out of the 867 hedge funds tracked by Insider Monkey. Buffett’s fund holds 22.05 million shares worth $1.30 billion in the corporation.

In December, Goldman Sachs analyst Chris Shibutani initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY), rating the stock as “Buy” and setting a price target of $72. The number of hedge funds tracked by Insider Monkey having stakes in Bristol-Myers Squibb Company (NYSE:BMY) grew to 74 in Q3, up from 73 in the preceding quarter.

In its fourth-quarter 2020 investor letter, Wedgewood Partners highlighted a few stocks, and Bristol Myers Squibb Co (NYSE:BMY) is one of them. Here is what the fund said:

“Bristol-Myers Squibb recently reported accelerating sales as much of the medical services industry returned to work. The Company continues to expect double-digit earnings growth over the next few years, driven by existing drugs, in addition to a broad pipeline of new drugs and indications. While the market remains fixated on a couple of patent expirations that could occur over the next several years, we think this is well-known at this point, yet the market still undervalues a couple of key acquisitions the Company has made in the past few years, particularly Celgene, which was acquired for a song.”